Biomedical Catalyst relaunches with £30 million

microbiologist working with sample in biomedical laboratory

The latest round of Innovate UK's Biomedical Catalyst will soon open for applications. From Monday 27th July, UK-registered SMEs can apply for a share of up to £30 million to develop a product or process that provides an innovative solution to a health and care challenge. Your project’s total eligible costs must be between £250,000 and £4 million.


This competition combines the early and late-stage strands of the Biomedical Catalyst. The aim of an early-stage award is to create a data package that is sufficient to support the testing of your product or process in a clinical setting. Meanwhile, the late-stage award will test a well-developed concept and show its effectiveness. Projects can focus on any health and care sector or discipline. However, they must be aligned to one of the following innovation areas:

  • medical technologies and devices
  • stratified healthcare
  • advanced therapies (gene and cell therapies)
  • digital health
  • drug discovery
  • diagnostics

Applications that support innovation in the following areas are particularly welcomed: child health technologies, innovations that support clinical trials in the UK, and biomedical innovations that combat the threat of antimicrobial resistance.

What is the Biomedical Catalyst?

The Biomedical Catalyst was developed in 2012 to achieve three key objectives:

  1. Deliver growth to the UK life sciences sector.
  2. Deliver innovative life sciences products and services into healthcare more quickly and effectively.
  3. Provide support to academic and commercially-led research and development.

A recent report by Ipsos MORI found that the Biomedical Catalyst has successfully met its objectives. Key findings include that the Biomedical Catalyst has offered strong value for money, increased companies' R&D investment by 93%, and increased employment by 11 to 15 percent over 3 to 5 years. Steve Bates, CEO of the UK BioIndustry Association, welcomed the announcement of additional funding:

"The Biomedical Catalyst has provided entrepeneurs and SMEs access to crucial capital to grow and scale. This is a key part of the Government's efforts to ensure the UK is resilient to future threats to public health, as well as supporting the development of new life-changing medical treatments, diagnostics and devices."

This competition closes on the 7th October 2020. If you'd like to apply, get in touch with RedKnight today to arrange a free consultation.